• Completed

NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in RRMM

Updated: Jun 17

NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients


Anti-CD38 CAR-T

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients


The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.


Sponsor

Sorrento Therapeutics, Inc.

 

ClinicalTrials.gov Identifier: NCT03464916

Official Title: A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : March 14, 2018


Click here to see details on ClinicalTrials.gov

 

Biological: CAR2 Anti-CD38 A2 CAR-T Cells

 

Autologous Anti-CD38 A2 CAR2 T-cells

Autologous Anti-CD38 A2 CAR2-expressing T-cells (Code C156170)

Autologous Anti-CD38 A2 CAR2 T-cells

Autologous Anti-CD38 A2 CAR2-expressing T-cells

Autologous CAR2 Anti-CD38 A2 CAR T-cells

Autologous CAR2 Anti-CD38 A2 T-lymphocytes

Autologous CD38-A2 CAR2-expressing T-lymphocytes

 

Locations

United States, Florida

United States, Minnesota

United States, New York

United States, Pennsylvania




Posts Archive